AXELEAD Begins Operations
Takeda Pharmaceutical Company and Axcelead Drug Discovery Partners has announced the start of operations for...
Multiple Scientific Posters Supporting the Efficacy, Safety and Tolerability of Once-daily Latuda® (lurasidone) are Presented at the 27th ECNP Congress
Takeda and Sunovion have presented new evidence supporting the use of Latuda® (lurasidone), an atypical antipsychotic treatment for adults with schizophrenia, during multiple poster sessions at the 27th European College of Neuropsychopharmacology (ECNP).
New data presented support Latuda's short and long-term efficacy, as well as preventing relapse.
This new data also supports Latuda as a tolerable option for patients switching medication from risperidone, having a low propensity for weight gain with minimal effects on cardiovascular and metabolic parameters.
Download to find out more.
More About This Company
New Post-Hoc Analyses Extend Understanding of the Efficacy and Safety of Lurasidone in the Treatment of Schizophrenia
Takeda Pharmaceuticals International and Sunovion Pharmaceuticals has announced the results from three post-hoc analyses evaluating...
Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn’s Disease in the EU
Takeda Pharmaceutical Company today announced that a marketing authorisation application (MAA) has been submitted to...